IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Polymorphisms in the region of the interleukin-28B (IL28B) gene have recently been associated with spontaneous and treatment induced clearance of hepatitis C virus infection. The specific mechanisms of how IL28B polymorphisms affect HCV suppression remain unknown. It is a matter of ongoing debate how to incorporate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin. The eventual role of the IL28B genotype in new therapeutic regimes with direct antiviral agents needs to be explored in the ongoing and future clinical studies with these agents.
Original languageEnglish
Pages (from-to)317-322
Number of pages6
JournalActa Gastro-Enterol Belg
Volume74
Issue number2
Publication statusPublished - Jun 2011

Fingerprint

Dive into the research topics of 'IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?'. Together they form a unique fingerprint.

Cite this